The evolution of the alkaline phosphatase (AP) gene family has lead to the existence in humans of one tissue non-specific (TNAP) and three tissue-specific isozymes, i.e., intestinal (IAP), germ cell (GCAP) and placental AP (PLAP). In order to define the structural differences between these isozymes we have built models of the TNAP, IAP and GCAP molecules based on the 1.8 Å structure of PLAP (1) and have performed a comparative structural analysis. We have examined the monomer-monomer interface, as this area is crucial for protein stability and enzymatic activity. We found that the interface allows the formation of heterodimers between IAP, GCAP and PLAP but not between TNAP with any of the three tissue-specific isozymes.
INTRODUCTION
Alkaline phosphatases (E.C.3.1.3.1) (APs) are dimeric enzymes present in most, if not all, organisms (2) . They catalyze the hydrolysis of phosphomonoesters with release of inorganic phosphate (3) . Mammalian APs have low sequence identity with the E. coli enzyme (25-30%), but the residues involved in the active site of the enzyme and those coordinating the two zinc atoms and the magnesium ion are largely conserved and the catalytic mechanism deduced from the structure of the E. coli AP was proposed to be similar in eukaryotic APs (4) . In humans, APs are encoded by four distinct loci. Three isozymes are tissue-specific, i.e., intestinal AP (IAP), placental AP (PLAP) and germ cell AP (GCAP). They are 90-98% homologous, and their genes are clustered on chromosome 2, bands q34-q37. The fourth AP isozyme is tissue non-specific (TNAP) and is expressed in a variety of tissues throughout development. TNAP is about 50% identical to the other three isozymes, and its gene is located on chromosome 1, bands p36.1-p34 (5).
Our current understanding of the functional properties of mammalian APs comes largely from studies using PLAP and TNAP as paradigms. Isozyme-specific properties, such as the characteristic uncompetitive inhibition properties of mammalian APs (6) (7) (8) , their variable heatstability (9) and even their allosteric properties (10) have been attributed to a top, flexible loop (or crown domain) unique to mammalian APs. This domain is also responsible for collagen binding in the case of TNAP (9, 11) but does not appear to mediate the reported binding of PLAP to IgG (12, 13) .
The recent elucidation of the 1.8Å resolution structure of human PLAP (1) has facilitated further studies on the structure and function of mammalian APs. An analysis of the structuralfunctional relationship of residues conserved between the E. coli AP and the PLAP structure revealed a conserved function for those residues that stabilize the active site Zn and Mg metal ions while the non-homologous disulphide bonds differ in their structural significance and nonconserved residues take part in determining the heat stability and uncompetitive inhibition properties of mammalian alkaline phosphatases (14) . Deactivating mutations in the TNAP gene cause the inborn error of metabolism known as hypophosphatasia (15) , characterized by poorly mineralized cartilage and bones. The severity and expressivity of hypophosphatasia depends on the nature of the TNAP mutation (16) . The mapping of hypophosphatasia mutations to specific three-dimensional locations on the TNAP molecule has provided clues as to the structural significance of these areas for enzyme structure and function (17) . It appears clear that the function of TNAP in bone tissue consists in hydrolizing inorganic pyrophosphate to maintain a proper concentration of this mineralization inhibitor to ensure proper bone mineralization (18) .
However, the physiological role of the three tissue-specific human APs remains to be clarified.
It has been suggested that PLAP may be involved in the transfer of maternal IgG to the fetus (12, 13, 19) and evidence has accumulated indicating a role of PLAP in cell division in normal and transformed cells (20) (21) (22) (23) . Of considerable interest is the fact that human APs are abundantly expressed in tumor cells, and that their serum levels are often used as tumor markers (24) . Plasma TNAP levels can indicate the presence of osteosarcomas (25), Paget's disease (26) and osteoblastic bone metastates (27) . PLAP is a marker of cancer of the ovary, testis, lung, and the gastrointestinal tract (28) (29) (30) . GCAP is a particularly good marker of carcinoma-in-situ of the testis (31) (32) (33) and IAP is a marker of hepatocellular carcinoma (34) .
While APs are homodimeric molecules, the re-expression in cancer cells of more than one AP isozyme often results in the formation and release into body fluids of heterodimeric enzymes.
The Kasahara AP isoform was identified in a variety of human cancer cell lines (35, 36) and cancer sera and was later found to consist of heterodimers of the IAP and PLAP (37) . The human postnatal intestine also contains heterodimers of IAP and PLAP (38) . Ovarian cancer cells often express both PLAP and GCAP (39) and cell lines derived from these tumors have been shown to express PLAP/GCAP heterodimers (40, 41) . However, no heterodimers have ever been reported between any of the tissue-specific APs and TNAP. The fact that APs can form heterodimers is of structural significance since APs are non-cooperative allosteric enzymes where the stability and the catalytic properties of each monomer are controlled by the conformation of the second subunit (10) . This means that the properties of the heterodimeric enzymes do not correspond to the weighted average of each homodimeric counterpart. Understanding the behavior of AP heterodimers is also of biological significance since, in tissues such as the bovine intestine where up to seven IAP isozymes with differing kinetic properties are co-expressed (42), the formation of heterodimers can give rise to significant functional complexity and novel substrate specificities.
In this study, we have build three-dimensional models of GCAP, IAP and TNAP based on the 1.8Å PLAP structure. We have analyzed the homodimer interface and the active site cleft of each modeled isozyme structure. This analysis has allowed us to understand the restrictions observed in APs heterodimer formation, while also defining a fingerprint of the active site characteristic of each AP isozyme
MATERIALS AND METHODS

Modeling of IAP, GCAP and TNAP and structural analysis
The PLAP dimer was generated from the coordinates of the PLAP structure (entry code 1EW2, (1) by using the symmetry operation corresponding to the C2221 space-group. The GCAP, IAP and TNAP sequences were aligned to the PLAP sequence using the program BLAST (43; http://www.ncbi.nlm.nih.gov/gorf/bl2.html). The PLAP and GCAP molecules display 98% identity, with no insertion or deletion relative to PLAP. The IAP and PLAP molecules show 87% identity and 91% homology, with no insertion or deletion relative to PLAP. The TNAP and PLAP molecules, however, display 57% identity and 74% homology, and TNAP has four insertions of one residue, one insertion of three residues, and one deletion of two residues relative to PLAP.
The GCAP, IAP and TNAP homodimeric models, and the PLAP/GCAP, PLAP/IAP, and PLAP/TNAP heterodimeric models were constructed using the sequence alignment as found with BLAST, the coordinates of the PLAP dimer, and the program MODELLER (44) . The quality of the model geometries was checked with PROCHECK (45) . Each model was superimposed to the structure of PLAP using the program ALIGN (46) .
The protein surface, interface surface, and residue accessibility were calculated with the program AREAIMOL as implemented in the CCP4 package (47) . The interactions between the two monomers were calculated with the program CONTACT as implemented in CCP4. The definition of secondary structure of proteins given a set of 3D coordinates (DSSP) algorithm (48) as implemented in TURBO was used to calculate secondary structures.
RESULTS AND DISCUSSION
Geometry of the GCAP, IAP and TNAP models
The model of GCAP, IAP and TNAP, listed in the order of structural similarity, were built from the PLAP structure using the sequence alignment shown in Figure 1 . This figure also shows the secondary structures, the residues involved in the homodimer interface, the surface residues, and those residues in the active site. As expected, the overall structure of each model is very close to that of PLAP (Table I ). The program used to build the models optimizes the geometry and the quality of the Ramachandran plot is equivalent for each model than for the PLAP structure. The secondary structures are conserved with those of PLAP, except for one α-helix in TNAP which is lost, due to a two residues deletion (Fig. 1) . Finally, the overall surface of each model, as well as the surface buried at the interface of each homodimer is similar to that of PLAP, showing that residue accessibility has not been affected by the substitutions performed in MODELLER (Table   I) .
Monomer-monomer interface in human APs
The overall surface buried at the interface varies between 4134 and 4244 Å 2 per monomer (Table I) , which corresponds to about 25% of the overall protein surface, and comprises about 90 residues per monomer that bury more than 10Å 2 of their surface upon dimerization. The residues involved in hydrogen bonds, salt bonds, hydrophobic stacking, or cation↑π interactions, are summarized in Table II . This table shows that the stabilizing interaction found in the four proteins are quite similar, although the IAP interface is slightly better stabilized that the others. The distribution of the residues at the interface shows two large clusters, and two small clusters, fully conserved between the four isozymes (Fig. 2) . The comparison of the interfaces reveals high conservation in the tissue-specific APs compatible with the fact that PLAP/GCAP or PLAP/IAP heterodimers form readily in nature. In TNAP, however, the substitutions E7K, R117E, N13R and P68R (PLAP numbering) would lead to repulsive forces at the interface, incompatible with the formation of heterodimers between TNAP and any of the tissue-specific APs. The formation of an heterodimer between TNAP and PLAP or any of the three tissue-specific APs would bring K7 in front of R117, E118 in front of E7, R13 in front of R135, and R69 in front of K81 (Fig. 3) .
Three of these repulsive interactions are clustered in the same area and can probably not be compensated by neighboring residues. The existence of these repulsive interactions is the most likely explanation for the absence of heterodimer formation between TNAP and any tissuespecific isozyme. The models of PLAP/GCAP, and PLAP/IAP hetrodimers confirm that the interactions at the interface do not lead to sterical hindrance, or repulsive forces (Table III) . The type and number of interactions observed in both heterodimers are very similar to those present in the corresponding homodimers with only slight differences due to sequence differences, or side chain flexibility. The PLAP/GCAP heterodimer is difficult to distinguish from a PLAP or GCAP homodimer since there are only 9 substitutions between these two isozymes and none of those differences affect the monomer-monomer interface (Fig. 3b) . In contrast, PLAP/IAP heterodimers lead to a protein where one monomer is enriched in ionic residues, and the other monomer in neutral or aliphatic residues (Fig. 3c) . Our model predicts the testable hypotheses that introducing the E7K, N13R, P68R mutations in PLAP would prevent PLAP homodimer formation, but would allow PLAP/TNAP heterodimer formation. The corresponding substitutions in TNAP, i.e., K7E, R13N, R69P, and E118R should allow heterodimer formation between TNAP and any of the three tissue-specific APs.
Active site cleft:
As has been described in detail before, the single-most important difference between PLAP and GCAP is the E429G substitution (PLAP numbering) which effectively converts PLAP into an enzyme with the kinetic, inhibition and heat stability properties of GCAP (6-10, 14, 49, 50) . E429 is located in the immediate neighborhood of the active site Zn1 (Fig. 4) and the nature of this residue confers completely different ionic as well as steric properties to the immediate surrounding of the active site, i.e., E429 in PLAP has a theoretical pKa around 4.3; G429 in GCAP has no side chain and provides important flexibility to the neighboring loop; S429 in IAP is neutral and polar; and H434 in TNAP has a theoretical pKa of 6.0. The close proximity of this residue to the active site suggests that it is directly involved in substrate binding. The change in side-chain and pKa can therefore selectively affect the nature of the substrate favored to bind to the active site of each AP isozyme.
On the upper part of the active site cleft, we observe a large cluster composed of R314, Y276, R326, R323 and R420, surrounded by E321 and E418 (Fig. 4) . This cluster, located at 11-17 Å from the phosphate group, exists in PLAP and GCAP, but not in IAP or TNAP and is particularly interesting since it includes residues which are often found at protein-protein interfaces (51, 52) . Interestingly, E418 and R420 were included in a region of homology that was proposed as a putative protein-protein interaction domain in PLAP (53) . The clear identification of this cluster at the roof of the active site is compatible with the notion that PLAP and/or GCAP may act as phosphoprotein phosphatases or as phosphotransferases. In this case this proteinprotein interaction domain may serve to stabilize the polypeptide chain serving either as substrate or as a phosphate acceptor.
On the lower part of the active site cleft, K87, F107, E108, R166, N167, Y169 and E429 from one monomer, and Y367 from the second monomer form a hydrophobic pocket in PLAP (Fig. 4) . This hydrophobic pocket, which involves residues from both monomers, is conserved in GCAP and IAP except at position 87 in IAP that displays the conservative substitution K87R. In TNAP, among the eight residues of this pocket, we observe five substitutions: K87A, F107E, Q108G, N167D, and E429H (PLAP numbering). These substitutions remove the hydrophobic character converting it into strongly ionic in TNAP. Therefore, the properties of this pocket in the case of TNAP are completely different to those of PLAP, GCAP or IAP. These findings correlate well with the differential behavior of the AP isozymes towards uncompetitive inhibitors, i.e., PLAP, GCAP, and IAP are inhibited by L-Phe but not by L-homoarginine, while TNAP is inhibited by L-homoarginine but not by L-Phe (2, 5) . The location and orientation of this pocket with regard to the phosphoseryl intermediate during catalysis (4) suggests that it may participate in stabilizing the phosphate-donor at the first step of the reaction. Therefore, the substrate of a tissue-specific APs or of TNAP must display ionic properties compatible with the highly divergent ionic properties of the corresponding pocket.
Thus, we have found three regions at the active site cleft which characterize each human AP. PLAP contains E429, the R-Y cluster at the roof, and the hydrophobic pocket at the floor of the cleft; GCAP contains G429, the R-Y cluster, and the hydrophobic pocket; IAP contains S429, no R-Y cluster but has the hydrophobic pocket while TNAP contains H429, no R-Y cluster, and a highly ionic pocket at the floor of the cleft. This suggests that the tissue-specific APs and TNAP are likely to have very different substrate specificities.
Concluding remarks
This structural analysis of the four human APs reveals important differences between the human AP isozymes that may provide clues as to their individual tissue-specific functions. Our analysis of the monomer-monomer interface provides the structural basis behind the formation of PLAP/GCAP and IAP/PLAP heterodimeric enzymes found expressed during development and in cancer cells. This analysis also provides a rational explanation for the lack of heterodimer formation between TNAP and any of the tissue-specific isozymes. At the active site cleft, we have defined a fingerprint characteristic of each AP isozyme. This fingerprint is compatible with the hypothesis of isozyme-specific specialization for a phosphate-donor or phosphate-acceptor in the case of transphosphorylation reaction.. Rmsd : Root mean squared deviation n.a: non applicable Table II : Hydrogen bonds, salt bonds, hydrophobic stacking, and cation-π interactions in AP homodimer interfaces. Residues in red correspond to an interaction which involves the side chain of the residue; residues in blue correspond to an interaction which involves the main chain of the residue and residues in violet are involved in a hydrophobic stacking or cation-π interaction. The interactions corresponding to the homodimeric interfaces, the symmetrical interactions are not given. N13 -H460  N13 -H460  N13 -H460  Q15 -S456  T50 -D436  T50 -D436  T50 -D436  T51 -D441  T50 -D436  T50 -D436  T50 -D436  T51 -D441  R53 -D436  R53 -D436  R53 -D436  R54 -D441  P65 -K81  P65 -K81  P65 -K81  E66 -K82  F68 -K81  F68 -Y83  P75 -H450  P75 -H450  P75 -H450  P76 -H455  P75 -G451  P75 -G451  P75 -G451  P76 -G456  Y83 -R370  Y83 -R370  Y83 -R370  Y84 -R374  V85 -R370  V85 -R370  V85 -R370  T86 -R374  D86 -R370  D86 -R370  D86 -R370  D87 -R374  H88 -P368  H88 -P368  Q88 -T368  Q89 -T372  Q88 -R370  H88 -G371  H88 -G371  Q89 -G375  Q88 -S372  F107 -Y367  F107 -Y367  F107 -Y367  F364 -G434  F364 -G434  F364 -G434  F368 -G439  Y367 -H432  Y367 -H432  Y367 -H432  Y371 -H437  S386 -P431  R383 -P426  A383 -P426  Q383 -P426  T388 -P431  Y399 -F401  (Y399/ Y399 Table III : Hydrogen bonds, salt bonds, hydrophobic stacking, and cation-π interactions in heterodimer interfaces. Residues in red correspond to an interaction which involves the side chain of the residue; residues in blue correspond to an interaction which involves the main chain of the residue and residues in violet are involved in a hydrophobic stacking or cation-π interaction. All the interactions from PLAP toward the second monomer are given.
PLAP-GCAP PLAP-IAP E7 -S113 E7 -S113 E7 -R117 E7 -R117  W12 Y83  W12 Y83  W12 K104  W12 K104  N13 -H460  N13 -H460  Q15 -S456  T50 -D436  T50 -D436  T50 -D436  T50 -D436  R53 -D436  R53 -D436  P65 -K81  P65 -K81  P75 -H450  P75 -H450  P75 -G451  P75 -G451  K81 -P65  K81 -F68  Y83 -W12  Y83 -W12  Y83 -F68  Y83 -R370  Y83 -R370  V85 -R370  V85 -R370  D86 -R370  D86 -R370  H88 -P368  Q88 -T368  Q88 -R370  H88 -G371  Q88 -S372  K104 -W12  F107 -Y367  F107 -Y367  S113 -E7  R117 -E7  R117 -E7  F364 -G434  F364 -G434  Y367 -T431  Y367 -H432  P368 -H88  T368 -Q88  R370 -V85  R370 -D86  R370 -D86  G371 -H88  S372 -Q88  A383 -P426  Q383 -P426  Y399 -R406  R406 -Y399  P426 -A383  P426 -Q383  H432 -Y367  G434 -F364  G434 -F364  D436 -T50  D436 -R53 D436 -R53 G451 -P75
Legend to Figures
Figure 1: Sequence alignment of human placental (PLAP), germ cell (GCAP), intestinal (IAP), and tissue-nonspecific (TNAP) alkaline phosphatases. The alignment shows the secondary structures of PLAP (<-->: alpha helix; <**>: beta sheet); the residues which are buried by more than 10Å upon dimerization (X); the residues with accessibility between 10 and 100 Å 2 (X) or higher than 100 Å 2 (X); and the residues located in the 12 Å sphere around the phosphate group in the active site (X). 
